CoChat
Sign Up
Cited by 144Systemic Lupus Erythematosus ResearchAdrenal Hormones and DisordersSystemic Sclerosis and Related Diseases

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.

van Vollenhoven, R F, Park, J L, Genovese, M C, West, J P, McGuire, J L·1999·Lupus
DOI 10.1191/096120399678847588
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine if dehydroepiandrosterone (DHEA) is beneficial in severe systemic lupus erythematosus (SLE). METHODS: A double-blinded, placebo-controlled, randomized clinical trial in 21 patients with severe and active SLE, manifestated primarily by nephritis, serositis or hematological abnormalities. In addition to conventional treatment with corticosteroids +/- immunosuppressives, patients received DHEA 200 mg/d vs. placebo for 6 months, followed by a 6-month open label period. The primary outcome was a prospectively defined responder analysis, based on a quantitatively specified improvement of the principal severe lupus manifestation at 6 months. RESULTS: Nineteen patients were available for evaluation at 6 months. Baseline imbalance between the groups was noted, with the DHEA group having greater disease activity at baseline (P<0.05 by physician's global assessment). Eleven patients were responders: 7/9 patients on DHEA vs. 4/10 patients on placebo (P<0.10). Of the secondary outcomes, mean improvement in SLE disease activity index (SLE-DAI) score was greater in the DHEA group (-10.3+/-3.1 vs. -3.9+/-1.4. P<0.07). Bone mineral density at the lumbo-sacral spine showed significant reduction in the placebo group, but was maintained in the DHEA group. CONCLUSION: DHEA therapy, when added to conventional treatment for severe SLE, may at most have a small added benefit with respect to lupus outcomes, but baseline imbalances in the study population limit the generalizability of the results. DHEA appears to have a protective effect with respect to corticosteroid-induced osteopenia in such patients.

Overview

Integrity signals

Registry

Crossref · 10.1191/096120399678847588

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. van Vollenhoven RF, 1992, Arthritis Rheum, 35, S207
  2. Lahita RG, 1992, J Rheumatol, 19, 447
  3. van Vollenhoven RF, 1998, J Rheumatol, 25, 285

Cited by

Sorted by citations

See all 144

Related

See all

Metadata

Authors
van Vollenhoven, R. F., Park, J. L., Genovese, M. C., West, J. P., & McGuire, J. L.
Affiliations
  • Division of Immunology & Rheumatology, Stanford, University Medical Center; Department of Rheumatology, Karolinska Hospital, Stockholm, 17176 Sweden
  • Stanford Medicine (US)
ORCID
Genovese, M C
Venue
Lupus
Publisher
SAGE Publications
Published
1999-03
Volume
8
Issue
3
Pages
181-187
ISSN
  • 0961-2033 (ISSN-L)
  • 1477-0962
DOI
10.1191/096120399678847588
OpenAlex
W2117480041
Cited by
144
References
23
Citations by year
2024: 1 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 4
FWCI
7.29
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Lupus (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p60ar020610-19)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-20610)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
dehydroepiandrosterone, systemic lupus erythematosus, lupus nephritis, serositis, hematological abnormalities, bone mineral density, SLE disease activity, adjunctive therapy, immunosuppressive therapy
MeSH terms
Adrenal Cortex Hormones, Adult, Dehydroepiandrosterone, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Bone Density, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review